AccurKardia

health AImedtechdigital health

StageSeed Stage/Series Seed

YC batchNot a YC-backed startup, but has participated in accelerator/incubator programs including MedTech Innovator and Mayo Clinic Platform Accelerate

Raised$4.11M to $10.2M

Founded2019

Employees17

LocationNew York, NY

ValuationNot publicly disclosed

About

AccurKardia is an ECG-led diagnostics software company transforming ECG data into a more powerful diagnostic tool and broad biomarker to improve patient outcomes and save lives globally. Its cloud-based platform includes AccurECG™, an FDA-cleared Class II software as a medical device (SaMD) that delivers fully automated, near real-time ECG interpretation and integrates seamlessly into existing clinical workflows. AccurECG™ was named “Best New ECG Technology” at the 2025 MedTech Breakthrough Awards. AccurKardia’s pipeline includes AK+ Guard™—an AI-driven hyperkalemia detection solution using Lead I ECG data to help identify life-threatening high potassium levels earlier in patients with CKD and ESRD—which received FDA Breakthrough Device Designation and acceptance into FDA’s Total Product Life Cycle (TAP) program in December 2024; and AK-AVS™, an AI model for aortic stenosis detection via 12-lead ECGs, which received FDA Breakthrough Device Designation in October 2024. AccurKardia completed the 2024 MedTech Innovator (MTI) cohort and was one of five companies selected for the American Heart Association’s inaugural Heart & Brain Health Accelerator track within MTI. AccurKardia also completed Cohort 3 of Mayo Clinic Platform_Accelerate in 2023. (AK+ Guard™ and AK-AVS™ are investigational and not commercially available.)

Product

Value proposition: AI-powered ECG interpretation and biomarker capabilities to improve diagnostic outcomes and patient lives.
Regulatory: FDA 510(k) clearance for AccurECG; AK-AVS and AK+ Guard not FDA-cleared for US clinical use (research use only)

Founders

Juan C. Jimenez — Co-Founder & CEO
Mohamed Sadeq Ali — Co-founder, CPO & CTO
Tony M. Kuttiachen — Co-Founder & GM Cardiac Monitoring
Naveen Srinivas — Co-Founder & Advisor
John Fox — Co-Founder & Board Member

Products

AccurECGAK-AVSAK+ Guard

Key features

FDA-cleared flagship AccurECG for automated ECG interpretationAI-driven interpretation of visible and hidden signals in ECGsExtending ECG use to novel applications and conditionsResearch-use-only AK-AVS and AK+ Guard with ongoing development

Technologies

Artificial intelligenceECG signal analysisbiomarker developmentFDA 510(k) pathway (reference)

Certifications

FDA 510(k) clearance (K252361)FDA recognition/clearance referenced in materials

Competitors

other ECG interpretation/biomarker startups and established ECG vendors

Investors

MedTech InnovatorMayo Clinic PlatformPopular Impact FundFox VenturesRoot NYC

News

AccurKardia Revenue 2025: $1.5M Est. ARR, $4.6M Valuation · 2025-09-18T00:00:00.000Z
AccurKardia Secures FDA 510(k) Clearance of and Launches AccurECG 2.0 · 2026-01-08T00:00:00.000Z
AccurKardia Raises $2.7M Seed Round to Expand AI-Powered ECG Diagnostics - VC Tavern · 2026-05-12T20:19:02.000Z
AccurKardia Secures Second FDA Clearance for AccurECG 2.0 to Tackle Cardiac Backlogs · 2026-01-09T15:00:00.000Z
AccurKardia and Wellysis Form Multi-Year Strategic Partnership to Deliver End-to-End Cardiac Monitoring · 2026-07-09T13:00:00.000Z
Study Shows AccurKardia’s AI-Enabled ECG Can Detect Aortic Stenosis Years Before Valve Replacement and Improve Mortality Risk Prediction · 2026-02-10T00:00:00.000Z

Browse similar startups

Related startups

Alike Nutrition — New York, NY
Amherst Pediatric Assoc — Buffalo, NY
AppointmentNotify, Inc. — New York, NY
Arkham Talent — New York, NY
Ascendia AI — New York, NY
Avon Health — New York City, NY
Colsia — Dover, DE
CorFigo, Inc. — Montclair, NJ
MassDevice — Cleveland, OH
Relief Cardiovascular — Costa Mesa, CA
SightGlass Vision, Inc. (United States) — Dallas, TX
SoundPass Medical — Salt Lake City, UT

Profile updated Jul 29, 2026. Sources: accurkardia.com, linkedin.com, businesswire.com